Evidence map›Paper›PMID 41924387›Full record

ArticleTherapeutic advances in gastroenterology2026

Increased failure of budesonide MMX for ulcerative colitis during the COVID-19 pandemic: a population-based study.

Stephanie Coward, Karen J B Martins, Scott Klarenbach, Lawrence P Richer, Christopher Ma, Remo Panaccione, Cynthia H Seow, Karen Kroeker, Frank Hoentjen, Laura E Targownik and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Stephanie CowardInflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, AB, Canada.ORCID https://orcid.org/0000-0003-0675-7226
Karen J B MartinsReal World Evidence Unit, University of Alberta, Edmonton, AB, Canada.ORCID https://orcid.org/0000-0002-3400-7214
Scott KlarenbachReal World Evidence Unit, University of Alberta, Edmonton, AB, Canada.ORCID https://orcid.org/0000-0002-8611-1056
Lawrence P RicherReal World Evidence Unit, University of Alberta, Edmonton, AB, Canada.ORCID https://orcid.org/0000-0002-6897-8668
Christopher MaInflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, AB, Canada.ORCID https://orcid.org/0000-0002-4698-9948
Remo PanaccioneInflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, AB, Canada.ORCID https://orcid.org/0000-0002-5247-940X
Cynthia H SeowInflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, AB, Canada.ORCID https://orcid.org/0000-0002-1551-9054
Karen KroekerDivision of Gastroenterology, Department of Medicine, University of Alberta, Calgary, AB, Canada.
Frank HoentjenDivision of Gastroenterology, Department of Medicine, University of Alberta, Calgary, AB, Canada.ORCID https://orcid.org/0000-0001-5314-4452
Laura E TargownikDivision of Gastroenterology and Hepatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
Gilaad G KaplanInflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, 3D03-18, 3280 Hospital Dr. NW, Calgary, AB T2N 4Z6, Canada.ORCID https://orcid.org/0000-0003-2719-0556

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Corticosteroids induce remission in ulcerative colitis (UC) but are associated with adverse effects, including prednisone ⩾20 mg/day associated with serious COVID-19 outcomes. Objectives: To evaluate the risk of rescue prednisone use following budesonide multimatrix system (MMX) initiation in newly diagnosed individuals with UC before and during the COVID-19 pandemic. Design: Population-based cohort study. Methods: We conducted a population-based study in Alberta, Canada, identifying adults with incident UC (2018-2022). Courses of budesonide MMX were examined for treatment failure, defined as prednisone rescue or inflammatory bowel disease-specific hospitalization within 90 days. Outcomes were compared between prepandemic (before April 2020) and pandemic periods using Cox proportional hazards models. Results: Among 269 dispensings of budesonide MMX (38 with multiple courses), 30.5% required rescue prednisone and 6.7% resulted in hospitalization. Budesonide MMX dispensing declined during the pandemic wherein, the hazard of prednisone rescue increased (HR 1.64; 95% CI: 1.01-2.67). Conclusion: Budesonide MMX was prescribed less frequently during the COVID-19 pandemic, with increased treatment failure, underscoring pandemic-related disruptions in UC management.

Indexed as

adverse eventscorticosteroidsCOVID-19treatment failureulcerative colitis

Identifiers

PMID41924387
PMCPMC13036333

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.